One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
https://doi.org/10.1016/s0090-8258(22)01541-4
Copy DOI
Export
Save
Share
Cite Journal: Gynecologic Oncology |  Publication Date: Aug 1, 2022 |
Affiliation: The US Oncology Network, Arizona Oncology, University of Arizona, Creighton University, Centre Léon Bérard, Mersana Therapeutics (United States), Rigshospitalet, Kliniken Essen-Mitte, Universität Innsbruck, New York University Langone Medical Center, University of Oklahoma Health Sciences Center
Optimizing the dose of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC): A posthoc analysis of a phase 1b expansion study in ovarian cancer (319)
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
